focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS: Liberum Downgrades GlaxoSmithKline To Sell

Wed, 30th Jul 2014 09:03

LONDON (Alliance News) - The following UK shares received analyst recommendations Wednesday morning:
----------
FTSE 100
----------
SOCGEN CUTS NEXT PRICE TARGET TO 6737 (6820) PENCE - 'HOLD'
----------
TRADERS: NOMURA RAISES AB FOODS PRICE TARGET TO 2480 (2400) PENCE - 'REDUCE'
----------
BERENBERG RAISES REED ELSEVIER PRICE TARGET TO 960 (930) PENCE - 'HOLD'
----------
MORGAN STANLEY CUTS SAINSBURY TO 'EQUAL-WEIGHT' ('OVERWEIGHT')
----------
SOCGEN RAISES BP PRICE TARGET TO 550 (540) PENCE - 'BUY'
----------
DEUTSCHE BANK CUTS ROYAL MAIL PRICE TARGET TO 400 (486) PENCE - 'HOLD'
----------
LIBERUM CUTS GLAXOSMITHKLINE TO 'SELL' ('HOLD') - TARGET 1350 (1500) PENCE
----------
HSBC CUTS NEXT TO 'NEUTRAL' ('OVERWEIGHT') - TARGET 7350 PENCE
----------
UBS RAISES RECKITT BENCKISER PRICE TARGET TO 4550 (4450) PENCE - 'SELL'
----------
JPMORGAN RAISES GKN PRICE TARGET TO 460 (430) PENCE - 'OVERWEIGHT'
----------
DEUTSCHE BANK CUTS ST JAMES'S PLACE PRICE TARGET TO 925 (950) PENCE - 'BUY'
----------
JPMORGAN RAISES ST JAMES'S PLACE PRICE TARGET TO 924 (909) PENCE - 'OVERWEIGHT'
----------
CREDIT SUISSE RAISES SMITH & NEPHEW PRICE TARGET TO 890 (865) PENCE - 'NEUTRAL'
----------
NUMIS RAISES STANDARD CHARTERED TO 'ADD' ('HOLD') - TARGET 1400 (1340) PENCE
----------
CANACCORD RAISES BRITISH AMERICAN TOBACCO PRICE TARGET TO 2925 (2900) PENCE - 'SELL'
----------
FTSE 250
----------
HSBC INITIATES PHOENIX GROUP WITH 'OVERWEIGHT' - TARGET 825 PENCE
----------
BERENBERG CUTS THOMAS COOK PRICE TARGET TO 170 (200) PENCE - 'BUY'
----------
TRADERS: NOMURA CUTS BETFAIR TO 'REDUCE' ('NEUTRAL')
----------
LIBERUM CUTS PACE PLC PRICE TARGET TO 390 (420) PENCE - 'HOLD'
----------
JEFFERIES CUTS PACE PLC PRICE TARGET TO 425 (467) PENCE - 'BUY'
----------
BARCLAYS RAISES ELEMENTIS PRICE TARGET TO 246 (243) PENCE - 'UNDERWEIGHT'
----------
SOCGEN CUTS TULLETT PREBON PRICE TARGET TO 245 (305) PENCE - 'HOLD'
----------
HSBC RAISES TULLETT PREBON TO 'OVERWEIGHT' ('NEUTRAL') - TARGET 311 PENCE
----------
BARCLAYS CUTS TULLETT PREBON PRICE TARGET TO 265 (335) PENCE - 'EQUAL WEIGHT'
----------
UBS REMOVES TULLETT PREBON FROM 'LEAST PREFERRED LIST' DIVERSIFIED FINANCIAL
----------
UBS RAISES TULLETT PREBON TO 'NEUTRAL' ('SELL') - TARGET 250 (230) PENCE
----------
DEUTSCHE BANK RAISES RENTOKIL INITIAL PRICE TARGET TO 114 (109) PENCE - 'HOLD'
----------
NUMIS CUTS INFORMA PRICE TARGET TO 620 (645) PENCE - 'BUY'
----------
UBS CUTS INFORMA PRICE TARGET TO 500 (520) PENCE - 'NEUTRAL'
----------
BERENBERG CUTS INFORMA PRICE TARGET TO 520 (530) PENCE - 'HOLD'
----------
HSBC RAISES GREAT PORTLAND PRICE TARGET TO 737 (715) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES DIRECT LINE PRICE TARGET TO 270 (228) PENCE - 'NEUTRAL'
----------
JEFFERIES CUTS TATE & LYLE PRICE TARGET TO 685 (715) PENCE - 'HOLD'
----------
NUMIS CUTS HISCOX TO 'HOLD' ('ADD') - TARGET 710 (785) PENCE
----------
NUMIS RAISES RIGHTMOVE PRICE TARGET TO 3397 (3360) PENCE - 'BUY'
----------
CANACCORD CUTS JLT GROUP TO 'HOLD' ('BUY') - TARGET 1070 (1165) PENCE
----------
MAIN MARKET AND AIM
----------
JPMORGAN RAISES GEM DIAMONDS PRICE TARGET TO 235 (200) PENCE - 'OVERWEIGHT'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2014 Alliance News Limited. All Rights Reserved.


More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.